Tivantinib (ARQ 197)是一种口服、非三磷酸腺苷竞争性、选择性、小分子met原癌基因(c-MET)抑制剂。计算出的tivantinib抑制重组人c-MET的抑制常数(Ki)约为355 nmol/L c-MET是一种受体酪氨酸激酶，是肝细胞生长因子(HGF)的高亲和力受体。HGF/c-MET信号通路失调经常发生在人类癌症中[1]。

     Tivantinib对VEGF受体-3 (Flt4)、p21活化激酶3、钙调素依赖性激酶ⅱδ和Pim-1有微弱的抑制作用[1]。Tivantinib对多种人类肿瘤细胞系表现出细胞毒性活性，EC50范围为300-600 nmol/L [4]。值得注意的是，A549、H3122、PC9 (Del E746_A750)、PC9 GR4 (Del E746_A750/T790M)、HCC827、HCC827 GR6、H1993和EBC-1细胞系显示出对替伐替尼一定程度的敏感性，IC50s在0.36和0.8微米之间[5]。在肿瘤细胞系中，GTL-16、MKN-45、Hs746T、SNU-5、EBC-1、H1993、NCI-H441、A549、HCT-116、U87-MG、A2780和TOV-112D，tivantinib不依赖于c-MET基因扩增和MET蛋白表达而无差别地抑制细胞增殖，EC50范围为60至600 nmol/L。进一步的研究表明，tivantinib促进有丝分裂停滞，防止细胞重新进入G1，并驱动。

     Tivantinib已在多种人类肿瘤细胞系和人类肺癌、结肠癌、前列腺癌、胰腺癌和乳腺癌的异种移植模型中显示出抗肿瘤活性[1] [2] [3]。雌性4周龄无胸腺裸(nu/nu)小鼠用作实验动物。从细胞注射后14至21天开始，与对照组相比，120 mg/kg剂量的Tivantinib显著抑制了治疗动物骨中的肿瘤负荷。增加tivantinib的剂量可减少溶骨性病变的数量和范围[6]。

产品性质：

Cas No.:905854-02-6

别名:(3R,4R)-3-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮,ARQ-197;ARQ197

化学名: (3S,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione

Canonical SMILES:O=C([C@H](C(C1=CC=C2)=CN3C1=C2CCC3)[C@@H]4C5=CNC6=CC=CC=C56)NC4=O

分子式:C23H19N3O2

分子量:369.42

溶解度:≥ 18.471mg/mL in DMSO

储存条件:Store at -20°C

注意事项：

为了您的安全和健康，请穿实验服并戴一次性手套操作。

References:

[1].  Ryohei Katayama, Aki Aoyama, Takao Yamori, et al. Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition. Cancer Research, 2013, 73(10): 3087-3097.

[2].  Andrew J.Wagner, John M. Goldberg, Steven G. DuBois, et al. Tivantinib (ARQ 197), a Selective Inhibitor of MET, in Patients with Microphthalmia Transcription Factor–Associated Tumors. Cancer, 2012: 5894-5902.

[3].  N. Yamamoto, H. Murakami, T. Nishina, et al. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Annals of Oncology, 2013, 00: 1–7.

[4].  Cristina Basilico, Selma Pennacchietti, Elisa Vigna, et al. Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET. Clin Cancer Res, 2013, 19(9):2381-92.

[5].  Cristina Basilico, Selma Pennacchietti, Elisa Vigna, et al. Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET. Clinical Cancer Research, 2013, 19(9): 2381–92.

[6].  Sara Previdi, Giovanni Abbadessa, Francesca Dalò, et al. Breast Cancer–Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown. Mol Cancer Ther, 2011, 11(1):214-23.